The presence and upregulation of PD-L1 and PD-1 in prostate cancer correlate strongly with enhanced tumor malignancy, resistance to established therapeutic regimens, and a generally unfavorable patient prognosis [15,16,17]. The gene discussed is PDCD1; the disease is neoplasm.